What is a small volume parenteral?

small volume parenteral

When you’re entering the world of pharmaceutical manufacturing, or any allied industry or role, it is critical for you to understand the basic terms involved in the production process. You don’t want to be frantically Googling pharmaceutical jargon when your colleagues or clients are discussing a new process or product launch. When someone says heat exchanger, clean room, AMC or small volume parenteral, it would be ideal to know what exactly is going on from the get-go.

In this article, our focus is on parenterals – small volume parenterals, specifically. It covers the definition, specifications, standards and risks involved in small volume parenterals and their production. So that the next time an injectable, ophthalmic drop or other parenteral preparation is being discussed, you already know all the essential details and more.

What are parenterals?

Parenterals are a category of pharmaceutical preparations which are designed and produced to be administered any way other than orally. Like eye drops, they may be applied topically to external tissue. Like most vaccinations, they may be administered intramuscularly. As in the case of insulin delivery, there are also subcutaneously-administered parenterals. Other than these, parenterals may also be delivered intravenously or directly into specialised tissue like the spinal cord.

In all of these cases, the pharmaceutical product bypasses the alimentary canal; it is not subject to the chemicals which break down substances in the digestive system. It has a much shorter route into the bloodstream or body tissue, and is therefore usually faster-acting that oral solid dosages. For these reasons, parenterals must always be pyrogen-free. Further, other than in the case of biologics or other products which are not heat stable, they must undergo terminal sterilisation to achieve sufficient sterility levels. In situations where terminal sterilization is not possible, the product must be aseptically produced and packaged.

Parenterals are of two kinds – small volume parenterals, or SVPs and large volume parenterals, or LVPs. The names of the two varieties give away the main difference between them: that of volume. Large volume parenterals are ordinarily packed in containers greater than 100 ml and less than 1000 ml in volume. Generally packed as a single dose, they are often intended for intravenous administration. We will discuss small volume parenterals in more detail below, but before that, it is also important to note that LVPs and SVPs also differ in terms of number of doses in a single package as well as delivery method.

What is a small volume parenteral?

A small volume parenteral is any sterile pharmaceutical preparation packed in a volume of 100 ml or less. You are likely to find a small volume parenteral contained in a vial, ampoule, pre-filled syringe, or a squeezable container. A single dose usually rangse from 1 ml to 30 ml, so a single SVP container may contain more than one dose. Small volume parenteral applications range from otic and oral drops to vaccinations and local anaesthetics.

A small volume parenteral may be in either dry powder form or liquid form; it all depends on the stability and characteristics of the active substance. Depending on the form of the SVP, it may be composed of any of the following elements: solutes, active pharmaceutical ingredients (APIs), water for injection, antimicrobial agents, antioxidants, and some more.

Manufacturing a small volume parenteral

In specialised equipment, the selected combination of these elements is brought together under controlled conditions of temperature, pressure and pH. But the compounding of the product is just one part of the process; storage, transfer and filling processes are also designed to maintain the integrity of the small volume parenteral.

For starters, the compounding or manufacturing vessels used are operated in specific Grade c areas under laminar air flow, or LAF. This creates a particle-free working environment, reducing the risk of contamination. These vessels are usually charged with water for injection, or WFI. APIs, antimicrobials and other components are added to make up the volume of the SVP, followed by nitrogen sparging, sampling and quality analysis.

From here, the product is moved to a storage or holding vessel which is placed in a Grade B area, under positive nitrogen pressure. Pre-sterilisation with steam ensures that the vessel doesn’t introduce any contaminants into the small volume parenteral. And then, the product finally passes through a sterile filter to make its way to the filling line. This whole process should ideally be customisable in terms of moveability of skid system, insulation, level sensing, radar, CIP and SIPintegrations, and load cells to make sure that your installed system is perfectly suited to your requirements.

What are the risks and standards involved in small volume parenteral manufacturing?

In the pharma industry, safety and quality are of utmost importance. Manufacturing a small volume parenteral, specifically, has extremely high standards given that the risk they pose can also be very high. Since SVPs enter directly into our organs, tissues or blood, their fast action has the potential to cause widespread damage. So there is absolutely no room for error at all.

Quality standards:

In pharma production, international standards for products and processes are outlined in some prominent pharmacopoeia like the US Pharmacopoeia, the European Pharmacopoeia and the Japanese Pharmacopoeia. Following the prescriptions of these global standards ensures that your small volume parenteral is acceptable in markets around the world. These documents provide guidance on good manufacturing practices, permissible levels of endotoxins, standards for particulate and microbial presence, and recommended methods to achieve different purity levels. Essentially, they provide a guide, a recipe, for you to reference as your company embarks on the small volume parenteral manufacturing journey.

Sterilisation:

If the final product is heat stable, the entire production process need not be aseptic, though sanitary standards would still be fairly high. In the case that terminal sterilisation is not being carried out, each part of the process must be aseptic. In both cases, the vessels, equipment, piping and other containers which come in contact with the small volume parenterals should be sterilised separately. This includes vials, ampoules, closures, filtration equipment and more. Moist heat, dry heat, special gases or radiation may be employed to achieve desired levels of sterility.

Quality testing:

When it comes to sterile products like small volume parenterals, testing is effectively a destructive process. If a sample is drawn for testing, that particular unit cannot be used because its sterility has been compromised by the test. This is why when it comes to sterile products, sterile standards are built into the process.

The above mentioned sterilisation standards are an important part of the process; but they are only one part of the process. For both drug and liquid injection manufacturing, sections of the plant need to be separated as per the process occurring there. Further, warehousing, washing, sterilisation, compounding, storage, packaging and labelling also all deserve separate sections to prevent cross-contamination.

Even after ensuring sanitary standards during production, product testing is a must at different stages of production and packaging. Since the process is destructive, a few samples are chosen from each lot to be tested. They undergo tests to measure sterility, pyrogens, bacterial endotoxins and other potential contaminants. The leaker’s test checks that ampoules are properly sealed; the clarity test checks for particulate contamination.

All of these processes must be accompanied by documentation. Without record-keeping, there is no way for you or for regulators to look back on the temperature, humidity, pressure and microbial presence under which your product was made. There is no way to prove the quality of your product in the future. This is why environmental monitoring data, simulation trail records as well as validation documentation must remain updated and secure with you.This case study and this project for a major Indian cosmetics company display TSA’s expertise in solving a range of high purity and process challenges. Not only does our range of products and services meet the highest industry standards, but each piece of equipment is customisable to your specific needs. Check out TSA’s small volume parenteral manufacturing range and reach out to us for a chat about how we can solve for you.

Share this post:

For 20 years, we’ve been the go-to problem-solvers for high-purity and injectable process applications in the pharma and biopharma industry. We are relentless about continuous process improvement and upskilling, elevating ourselves and our technology so you can get the job done more efficiently with cost optimisations. Use the form below to schedule a call back from our team.

Name(Required)
This field is for validation purposes and should be left unchanged.

Hetal Panchal is the Vice President in Operations department of TSA Process Equipments (A Thermax Group Company) since 1 s t October 2012.

Holding a qualification in Production Engineering and 28 years of industry experience, he specializes in designing advanced equipment for the pharmaceutical sector. His expertise lies in optimizing production lines, improving efficiency, and ensuring compliance with regulatory standards.
Focused on innovation, he has developed systems that enhances productivity, minimizes downtime, and maintains product quality. Staying current with technological trends, they contribute to ongoing improvements in the industry.
His extensive experience has helped identify opportunities for innovation, streamlining operations and reducing costs. Through his specialized knowledge, more efficient manufacturing processes and higher-quality outputs in pharmaceutical production are delivered.

B.C. Mahesh is the Chairperson of TSA Process Equipment Pvt. Ltd. since Feb 2024.

B.C. Mahesh became a member of the Executive Council in August 2013. He is responsible for the Industrial Product Business (IPB), which consists of Process Heating, Absorption Cooling & Heating Solutions, Water and Waste Solutions, Air Pollution Control, Steam Engineering, Channel Business Group, International Business Group, and Enterprise Sales businesses.
As part of IPB, he also oversees the following wholly-owned subsidiaries
of Thermax – Danstoker, PT Thermax International Indonesia and Rifox.Mahesh joined Thermax as a graduate trainee in 1988 and handled the Materials function for various businesses, including global sourcing, till 1996.
He moved to the Power division(P&ES) and grew to the position of Sales Head and subsequently Head of Projects. He took over as the Head of the SBU for Medium Power Plants in 2009 and finally as Head of Power business in 2012.
Mahesh has worked with Thermax for over 30 years in many functions such as manufacturing, supply chain, sales and marketing, and project management, and has played a significant role in the strategy, expansion and diversification of the Power business.Mahesh completed his Mechanical Engineering from the Visvesvaraya Regional College of Engineering, Nagpur in 1988.

Vishal Mehra is the Director of TSA Process Equipment Pvt. Ltd. since Feb 2024.

Mr. Vishal Mehra is currently serving as the Strategic Business Unit Head for Water & Waste Solutions (WWS) at Thermax Limited. Additionally, he holds a directorial position at TSA Process Equipment, which is known for its expertise in ultra-pure and high-purity water technologies and was recently acquired by Thermax.With over 22 years of experience in the industry, Mr. Mehra’s professional focus includes water management solutions, advanced technology development, and business strategy.
His areas of interest encompass cutting-edge technology, growth strategies, organizational effectiveness, and development.
Mr. Mehra is well qualified in business management and strategy transformation, having completed the Senior Executive Program in Business Management and Strategy Transformation from London Business School. This advanced education supports his extensive experience and expertise in the field.

Sandeep Deshpande has been the Director of TSA Process Equipments Pvt. Ltd. since February 2024.

Currently, he serves as the Head of Corporate Finance and the Industrial Product Group at Thermax Limited. With over 21 years of experience in finance, he has developed expertise in financial consolidation, planning, reporting, costing, accounting, controlling and financial modeling.
Currently, he serves as the Head of Corporate Finance and the Industrial Product Group at Thermax Limited. With over 21 years of experience in finance, he has developed expertise in financial consolidation, planning, reporting, costing, accounting, controlling and financial modeling.
Sandeep is a qualified Cost Accountant Company Secretary, and holds a diploma in IFRS and an advanced diploma in financial management from XLRI. He has extensive experience in financial operations, including financial planning, MIS, budgeting, controlling, audits, and cash flow management. His expertise also spans financial reporting, consolidation, mergers and acquisitions, due diligence, business restructuring, and implementing Internal Financial Control (IFC) and Enterprise Risk Management (ERM). Additionally, Sandeep has hands-on experience with Oracle systems, automation, digitization, and business analytics. He is passionate about driving good governance, improving financial reporting, and leveraging automation and digitization to enhance business analytics.

Rajiv Parikh is the COO of TSA Process Equipments (A Thermax Group Company) since April 2024.

Rajiv is a highly accomplished professional with extensive experience in the pharmaceutical and FMCG sectors, specializing in high-purity and process vessels. He played a key role in establishing TSA Process Equipments Pvt. Ltd., driving its growth and success. His deep technical expertise, combined with a strong understanding of client needs, has enabled him to deliver innovative solutions to complex industry challenges.

Throughout his career, Rajiv has excelled in leadership and sales, consistently launching cutting-edge products that have positively impacted the market. His ability to build lasting client relationships and offer tailored solutions has earned him a reputation as a trusted industry leader.

With a background in Mechanical Engineering, Rajiv blends technical proficiency with strategic vision. His contributions have shaped industry standards and positioned him as a key influencer in the pharmaceutical and FMCG sectors.

Apurva Shah is the CEO of TSA Process Equipments (A Thermax Group Company) since April 2024.

With a career spanning over 24 years, Apurva is the visionary CEO of TSA Process Equipments, where he has led the company to new heights in the High Purity & process equipment industry. A graduate in Mechanical Engineering from Mumbai University, followed by an MBA in Business Management from NMIMS, He brings a strong technical foundation combined with a sharp strategic mindset.

His expertise lies in formulating and executing strategies that drive growth and operational efficiency. Over the years, he has cultivated a deep understanding of market dynamics, positioning TSA Process Equipments for continued success in a competitive landscape.

Outside of his professional pursuits. He is an avid reader, with a particular interest in fiction novels, which fuel his creativity and broaden his perspective.